DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20192643

Comparison of metabolic effects of glimepride and sitagliptin with metformin in patients suffering from type 2 diabetes mellitus in a tertiary care hospital

Preeti Singh, Ruchi Choudhary, V. K. Singh, Prithpal S. Matreja

Abstract


Background: Diabetes mellitus (DM) is one of the major causes of mortality & morbidity, and patient’s with better control of glycaemic parameters have lesser chronic complications associated with it. Though monotherapy with metformin is first choice for T2DM but is effective in less than 50% of patient and they should be managed with two drug therapy. Both Glimepiride and Sitagliptin are effective with metformin but there has been no study done in this region hence, we planned to study comparison of effects of glimepiride and sitagliptin with metformin in patient of T2DM.

Methods: This prospective, open-label, randomized study was done in all patient diagnosed with T2DM, not adequately managed by metformin alone. The patient was divided into two group G (Glimepiride with Metformin) and Group S (Sitagliptin with Metformin) and had a follow up at 3 and 6 months. The biochemical parameters were assessed at 12 weeks and 24 weeks.

Results: The result of this study show that both glimepiride and sitagliptin with metformin significantly (p<0.05) lowered both the fasting blood sugar as well as postprandial blood glucose at 3 and 6 months. Glimepiride was more effective in lowering (p<0.05) the plasma glucose at 3 months but both the drugs had comparable result at 6 months. This study also showed that glycosylated haemoglobin was lowered in both groups at three and six months as compared to Day 0 (p<0.05), with glimepiride having better control of glycosylated haemoglobin at 3 months with both groups having comparable result at 6 months.

Conclusions: To conclude, this study compared effects of sitagliptin and glimepiride on glycaemic parameters in patients of T2DM and found that both drugs had comparable results.


Keywords


Diabetes mellitus, Fasting blood sugar, Glycosylated haemoglobin, Post-prandial blood glucose

Full Text:

PDF

References


Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.

Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus-progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281(21):2005-12.

Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: A prospective, cross-sectional study at a tertiary care teaching hospital. J Basic Clin Pharm. 2013;4(4):82-7.

Lim PC, Chong CP. What's next after metformin? Focus on sulphonylurea: Add-on or combination therapy. Pharm Pract (Granada). 2015;13(3):606.

Nandy M, Mandal A, Banerjee S, Ray K. A prescription survey in diabetes assessing metformin use in a tertiary care hospital in Eastern India. J Pharmacol Pharmacotherapeut. 2012;3(3):273-5.

Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015;19(5):577-96.

Basit A, Riaz M, Fawwad A. Glimepiride: Evidence-based facts, trends, and observations (GIFTS). Vasc Health Risk Manag. 2012;8:463-72.

Moon JS, Ha KS, Yoon JS, Lee HW, Lee HC, Won KC, et al. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: Open-label, randomized, controlled study. Acta Diabetol. 2014;51(2):277-85.

Singh P, Khan FA, Hemnani TJ, Matreja PS, Singh VK. A prospective study to analyze the metabolic effects of Metformin with Glimepiride on type 2 Diabetic patients of North India. Ann Int Med Den. Res. 2016;2(4):242-5.

Singh P, Singh VK, Hemnani TJ, Matreja PS. A Prospective study on effectiveness of Sitagliptin with Metformin in Type 2 Diabetic patients in a Tertiary Care Hospital. Int J Med Res Prof.2016;2(3):246-8.

Gerrald KR, Van Scoyoc E, Wines RC, et al. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2012;14(6):1481-92.

Dicker D. DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34(Suppl 2):S276-8.

Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis. BMJ. 2012;344:e1369.

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled onmetformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194-205.

Shimoda S, Iwashita S, Sekigami T, Furukawa N, Matsuo Y, Ichimori S, et al. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. J Diabetes Invest. 2014;5(3):320-6.

Hou L, Zhao T, Liu Y, Zhang Y. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated haemoglobin with metformin monotherapy: A meta-analysis. Experiment Therapeut Med. 2015;9(4):1528-36.

American diabetes Asoociation. Diagnosis and Classification of Diabetes Mellitus. Diabetic care 2014;37(Suppl 1):S81-90.

Arechavaleta R, Seck T, Chen Y, Krobot KJ, O’Neill EA, Duran L, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160-8.

Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013;36:1067-73.

Srivastava S, Saxena GN, Keshwani P, Gupta R. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. J Assoc Physicians India. 2012;60(2):27-30

Muthukrishnan J, Dawra S, Marwaha V, Bishnoi JS, Narayanan CS. Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin? Indian J Endocrinol Metabol. 2012;16(Suppl 2):S474-6.

Kumar S, Pathak AK, Saikia D, Kumar A. Efficacy, safety and treatment satisfaction of glimepiride vs. Sitagliptin in combination with metformin in type 2 diabetes mellitus. J Clin Diagn Res. 2015;9(12):FC07-10.

Anjoom M, Dutta S, Meg MA, Verma A, Bawa S, Kant R. Comparative evaluation of combination of metformin and Glimepiride with that of metformin and Sitagliptin in type 2 diabetes mellitus with respect to glycaemic target. Int J Med Sci Public Health. 2015;4(4):476-80.